Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 477

1.

Steady-state and stopped-flow kinetic studies of three Escherichia coli NfsB mutants with enhanced activity for the prodrug CB1954.

Jarrom D, Jaberipour M, Guise CP, Daff S, White SA, Searle PF, Hyde EI.

Biochemistry. 2009 Aug 18;48(32):7665-72. doi: 10.1021/bi900674m.

PMID:
19580253
[PubMed - indexed for MEDLINE]
2.

Kinetic and structural characterisation of Escherichia coli nitroreductase mutants showing improved efficacy for the prodrug substrate CB1954.

Race PR, Lovering AL, White SA, Grove JI, Searle PF, Wrighton CW, Hyde EI.

J Mol Biol. 2007 Apr 27;368(2):481-92. Epub 2007 Feb 11.

PMID:
17350040
[PubMed - indexed for MEDLINE]
3.

Discovery and evaluation of Escherichia coli nitroreductases that activate the anti-cancer prodrug CB1954.

Prosser GA, Copp JN, Syddall SP, Williams EM, Smaill JB, Wilson WR, Patterson AV, Ackerley DF.

Biochem Pharmacol. 2010 Mar 1;79(5):678-87. doi: 10.1016/j.bcp.2009.10.008. Epub 2009 Oct 21.

PMID:
19852945
[PubMed - indexed for MEDLINE]
4.

Mechanism of CB1954 reduction by Escherichia coli nitroreductase.

Christofferson A, Wilkie J.

Biochem Soc Trans. 2009 Apr;37(Pt 2):413-8. doi: 10.1042/BST0370413. Review.

PMID:
19290872
[PubMed - indexed for MEDLINE]
5.

E. coli NfsA: an alternative nitroreductase for prodrug activation gene therapy in combination with CB1954.

Vass SO, Jarrom D, Wilson WR, Hyde EI, Searle PF.

Br J Cancer. 2009 Jun 16;100(12):1903-11. doi: 10.1038/sj.bjc.6605094. Epub 2009 May 19.

PMID:
19455141
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)--II. A comparison of an Escherichia coli nitroreductase and Walker DT diaphorase.

Knox RJ, Friedlos F, Sherwood RF, Melton RG, Anlezark GM.

Biochem Pharmacol. 1992 Dec 15;44(12):2297-301.

PMID:
1472095
[PubMed - indexed for MEDLINE]
7.

The bystander effect of the nitroreductase/CB1954 enzyme/prodrug system is due to a cell-permeable metabolite.

Bridgewater JA, Knox RJ, Pitts JD, Collins MK, Springer CJ.

Hum Gene Ther. 1997 Apr 10;8(6):709-17.

PMID:
9113510
[PubMed - indexed for MEDLINE]
8.

Generation of Escherichia coli nitroreductase mutants conferring improved cell sensitization to the prodrug CB1954.

Grove JI, Lovering AL, Guise C, Race PR, Wrighton CJ, White SA, Hyde EI, Searle PF.

Cancer Res. 2003 Sep 1;63(17):5532-7.

PMID:
14500391
[PubMed - indexed for MEDLINE]
Free Article
9.

Testing double mutants of the enzyme nitroreductase for enhanced cell sensitisation to prodrugs: effects of combining beneficial single mutations.

Jaberipour M, Vass SO, Guise CP, Grove JI, Knox RJ, Hu L, Hyde EI, Searle PF.

Biochem Pharmacol. 2010 Jan 15;79(2):102-11. doi: 10.1016/j.bcp.2009.07.025. Epub 2009 Aug 7.

PMID:
19665450
[PubMed - indexed for MEDLINE]
10.

E. coli nitroreductase/CB1954: in vitro studies into a potential system for feline cancer gene therapy.

Blackwood L, O'Shaughnessy PJ, Reid SW, Argyle DJ.

Vet J. 2001 May;161(3):269-79.

PMID:
11352484
[PubMed - indexed for MEDLINE]
11.

E. coli nitroreductase/CB1954 gene-directed enzyme prodrug therapy: role of arylamine N-acetlytransferase 2.

Mitchell DJ, Minchin RF.

Cancer Gene Ther. 2008 Nov;15(11):758-64. doi: 10.1038/cgt.2008.47. Epub 2008 Jul 4.

PMID:
18600257
[PubMed - indexed for MEDLINE]
12.

Sensitization of colorectal and pancreatic cancer cell lines to the prodrug 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) by retroviral transduction and expression of the E. coli nitroreductase gene.

Green NK, Youngs DJ, Neoptolemos JP, Friedlos F, Knox RJ, Springer CJ, Anlezark GM, Michael NP, Melton RG, Ford MJ, Young LS, Kerr DJ, Searle PF.

Cancer Gene Ther. 1997 Jul-Aug;4(4):229-38.

PMID:
9253508
[PubMed - indexed for MEDLINE]
13.

uvrB gene deletion enhances SOS chromotest sensitivity for nitroreductases that preferentially generate the 4-hydroxylamine metabolite of the anti-cancer prodrug CB1954.

Prosser GA, Patterson AV, Ackerley DF.

J Biotechnol. 2010 Oct 1;150(1):190-4. doi: 10.1016/j.jbiotec.2010.08.007. Epub 2010 Aug 19.

PMID:
20727918
[PubMed - indexed for MEDLINE]
14.
15.

Direct positive selection for improved nitroreductase variants using SOS triggering of bacteriophage lambda lytic cycle.

Guise CP, Grove JI, Hyde EI, Searle PF.

Gene Ther. 2007 Apr;14(8):690-8. Epub 2007 Feb 15.

PMID:
17301844
[PubMed - indexed for MEDLINE]
16.

Creation and screening of a multi-family bacterial oxidoreductase library to discover novel nitroreductases that efficiently activate the bioreductive prodrugs CB1954 and PR-104A.

Prosser GA, Copp JN, Mowday AM, Guise CP, Syddall SP, Williams EM, Horvat CN, Swe PM, Ashoorzadeh A, Denny WA, Smaill JB, Patterson AV, Ackerley DF.

Biochem Pharmacol. 2013 Apr 15;85(8):1091-103. doi: 10.1016/j.bcp.2013.01.029. Epub 2013 Feb 8.

PMID:
23399641
[PubMed - indexed for MEDLINE]
17.

Studies on the nitroreductase prodrug-activating system. Crystal structures of complexes with the inhibitor dicoumarol and dinitrobenzamide prodrugs and of the enzyme active form.

Johansson E, Parkinson GN, Denny WA, Neidle S.

J Med Chem. 2003 Sep 11;46(19):4009-20.

PMID:
12954054
[PubMed - indexed for MEDLINE]
18.

The expression of bacterial nitroreductase in transgenic mice results in specific cell killing by the prodrug CB1954.

Drabek D, Guy J, Craig R, Grosveld F.

Gene Ther. 1997 Feb;4(2):93-100.

PMID:
9081711
[PubMed - indexed for MEDLINE]
Free Article
19.

Crystal structure of quinone reductase 2 in complex with cancer prodrug CB1954.

Fu Y, Buryanovskyy L, Zhang Z.

Biochem Biophys Res Commun. 2005 Oct 14;336(1):332-8.

PMID:
16129418
[PubMed - indexed for MEDLINE]
20.

Investigation of alternative prodrugs for use with E. coli nitroreductase in 'suicide gene' approaches to cancer therapy.

Bailey SM, Knox RJ, Hobbs SM, Jenkins TC, Mauger AB, Melton RG, Burke PJ, Connors TA, Hart IR.

Gene Ther. 1996 Dec;3(12):1143-50.

PMID:
8986441
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk